Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.52 |
| ▸ | FPR2 | P25090 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613373 | 0.86 | L3MBTL1 (0.56) | L3MBTL1CA2CA1NAALAD2PTPN1 | |
| SCHEMBL4001530 | 0.85 | L3MBTL1 (0.57) | L3MBTL1CA2CA1NAALAD2PTPN1 | |
| SCHEMBL9489744 | 0.85 | L3MBTL1 (0.57) | L3MBTL1CA2CA1NAALAD2PTPN1 | |
| SCHEMBL4001531 | 0.85 | L3MBTL1 (0.57) | L3MBTL1CA2CA1NAALAD2PTPN1 | |
| SCHEMBL15145381 | 0.83 | L3MBTL1 (0.71) | L3MBTL1CA2CA1NAALAD2PTPN1 | |
| SCHEMBL4066390 | 0.82 | L3MBTL1 (0.69) | L3MBTL1ITGA4FPR2 | |
| SCHEMBL19969196 | 0.80 | NAALAD2 (0.78) | L3MBTL1NAALAD2MMENPSR1MEN1 | |
| SCHEMBL18180178 | 0.80 | NAALAD2 (0.78) | L3MBTL1NAALAD2MMENPSR1MEN1 | |
| SCHEMBL28965815 | 0.80 | L3MBTL1 (0.67) | L3MBTL1CA2CA1NAALAD2PTPN1 | |
| SCHEMBL28965814 | 0.80 | L3MBTL1 (0.67) | L3MBTL1CA2CA1NAALAD2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781640-B1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| CN-101044137-A | 2,4-di(aminophenyl)pyrimidine derivatives as plk inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-09-26 | — | — | CN | disclosed |
| EP-1781640-A1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-05-09 | — | — | EP | disclosed |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006021544-A1 | 2,4-DI(AMINOPHENYL) PYRIMIDINES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL1 849/4885CA2 4604/4885CA1 4848/4885 |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL1 849/4885CA2 4604/4885CA1 4848/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL1 849/4885CA2 4604/4885CA1 4848/4885 |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL1 849/4885CA2 4604/4885CA1 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.